National Institutes of Health selected Humanigen’s lenzilumab for its COVID-19 Big Effect Trial
On Jul. 27, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases and Humanigen had…
On Jul. 27, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases and Humanigen had…
On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…
On Jul. 27, 2020, Onconova Therapeutics announced that it had submitted an application with the National Institute of…
On Jul. 23, 2020, Dynavax Technologies and Medigen Vaccine Biologics (MVC) announced a collaboration to develop an adjuvanted…
On Jul. 22, 20120, Evotec announced that the U.S. Department of Defense (DoD) had awarded its Seattle-based subsidiary,…
On Jul. 22, 2020, RedHill Biopharma announced that it had submitted a Clinical Trial Application (CTA) with the…
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
On Jul. 20, 2020, Mateon Therapeutics announced the launch of its global observational study called ARTI-19, for Artemisinin…
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…
On Jul. 15, 2020, Atossa Therapeutics announced successful results from in vitro testing of AT-301, Atossa’s proprietary COVID-19…
On Jul. 14, 2020, Akebia Therapeutics announced the initiation of an investigator-sponsored study evaluating the use of vadadustat,…
On Jul. 14, 2020, Pascal Biosciences announced it had discovered certain cannabinoids that block replication of SARS-CoV-2, the…
On Jul. 10, 2020, the Imaging Platform at the Broad Institute of MIT and Harvard, together with industry…
On Jul. 9, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that it is partnering with Albany…
On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…
On Jul. 8, 2020, the National Institute of Allergy and Infectious Diseases announced it had established a new…
On Jul. 8, 2020, seventy-three countries warned that they were at risk of stock-outs of antiretroviral (ARV) medicines…
On Jul. 8, 2020, the Mount Sinai Health System, Emergent BioSolutions and ImmunoTek Bio Centers announced a collaboration…
On Jul. 8, 2020, Gilead Sciences announced data evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP…
On Jul. 8, 2020, Constant Therapeutics reported that its peptide drug TXA127 was tested in a series of…
On Jul. 8, 2020, the Fred Hutchinson Cancer Research Center was named the coordinating center for vaccine clinical…
On Jul. 8, 2020, scientists from Texas A&M University, biopharmaceutical company Pulmotect and MD Anderson Cancer Center announced…
On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had completed the initial in silico…
On Jul. 4, 2020, the World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering…
On Jul. 3, 2020, CytoDyn announced it had signed an exclusive Distribution and Supply Agreement with American Regent…
On Jul. 2, 2020, the U.S. Food and Drug Administration (FDA) approved Rukobia (fostemsavir), a new type of…
On Jul. 2, 2020, UConn announced a licensing deal with Connecticut Biotech, a startup company headquartered in South…
On Jul. 2, 2020, Regeneron and Sanofi announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400…